Dr John Lambert has over 18 years of drug discovery and development experience. His experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
His prior appointments included leadership roles in drug development, operations management and drug discovery (Biota Pharmaceuticals) - primarily working on the development of respiratory antiviral drugs.
As a senior director at Medicines Development for Global Health, Dr Lambert was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness.
Prior to working in the industry, Dr Lambert was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). He is also an experienced manager of both early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products.
